Beginning from the first case in China (December 2019), SARS-CoV-2 is severely affecting many countries around the world. In response to the global pandemic, researchers worldwide are using different approaches to develop a coronavirus vaccine at the earliest.
To protect COVID affected patients, CureVac AG is working on the development of mRNA-based drugs for vaccines and therapeutics.
CureVac is a reputed biopharmaceutical company with headquarters in Tubingen, Germany. Founded in 2000, CureVac is the first pharma company in the world that has successfully harnessed mRNA for medical purposes. The company is proud to be part of the international helping hands towards protecting masses from the novel coronavirus. The recent success of the company relates to the Rabies program that aims to fully protect humans with two doses of only one microgram (I millionth of a gram).
The company aims to provide a cost-effective and prophylactic vaccine using unique technology. At present, their team is working on mRNA technology to bring a rapid response to prevent spreading the virus. Since 2007, the company is engaged in the prophylactic vaccine and can produce mRNA vaccines on a colossal scale.
After the Paul Ehrlich Institute, CureVac is the second German company which has begun the trial phase for the vaccine against COVID-19.
To bring practical results and to speed up the development, production, and clinical process, CureVac is in contact with various health organizations such as CEPI (Coalition for Epidemic Preparedness Innovations) and BMGF (Bill and Melinda Gates Foundation.
About mRNA Technology
A natural messenger substance, the vaccine will be a trial to activate the human body against its defence mechanism. With the mRNA technology, it is expected that the human body will recognize the protein of the coronavirus and in response will activate its immune cells to produce antibodies and T-cells against it.
Mariola Fotin-Mleczek (Chief Technology Officer of CureVac) said, “With our unique RNA technology, we prepare the human body how to fight against the virus. Our expertise and disease understanding makes us able to come up with a solution for outbreak solutions like COVID-19.
As per the recent information on the Curevac COVID trial, the company has started human trials after the idea approved by regulators. The first trial by the German biotech firm will involve 168 volunteers, of whom 144 will be given the experimental vaccine.
Many countries are contributing to bringing the coronavirus vaccine. However, projections for how long it will take to develop a vaccine vary widely. Based on the experience and knowledge, researchers need at least a year to come up with an effective solution.
Once researchers successfully create a potential vaccine then brings into the notice of the Food and Drug Administration (FDA) to check its effectiveness.
The next phase is to complete Phase I, Phase II, and Phase III clinical trials to analyze the safety and effectiveness of the drug thoroughly.
The company is expected to begin the next clinical study with several thousand participants in autumn 2020. Even if CureVac remains successful in achieving favourable results, it depends on the regulatory authorities about the availability of the vaccine on the market.
- R-Pharm Coronavirus: Russia approves for Covid-19 treatment September 24, 2020
- Japan’s Homegrown COVID-19 Drug Hope Avigan Faces Rocky Future September 11, 2020
- Oxford Vaccine Enters Final Phase of COVID-19 Trials September 3, 2020
- Gilead’s Remdesivir: Australia approves for COVID 19 Treatment September 3, 2020
- MMR Vaccine: Prevention From Worst Symptoms of COVID 19 July 17, 2020